The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 117, Issue 4, 1999, Pages 744-750

  Kandioler Eckersberger, D ^a   Kappel, S ^a   Mittlbock, M ^a   Dekan, G ^a   Ludwig, C ^a   Janschek, E ^a   Pirker, R ^a   Wolner, E ^a   Eckersberger, F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IFOSFAMIDE; PROTEIN P53;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0032931246     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(99)70295-3     Document Type: Article

References (23)

1. FA Shepherd Future directions in the treatment of lung cancer Semin Oncol 21 1994 48S 62S
2. R Rosell J Gomez-Codina C Camps J Maestre J Padille A Canto A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 330 1994 153 158
3. W Eberhardt H Wilke G Stamatis M Stuschke A Harstrick H Menker Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial J Clin Oncol 16 1998 622 634
4. RO Dillman J Herndon SL Seagren WL Eaton Jr MR Green Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia Group B trial (CALGB) 8433 Trial J Natl Cancer Inst 88 1996 1210 1215
5. R Rosell A Font A Pifarre M Canela J Maurel A Arellano The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC Chest 109 1996 102S 106S
6. Y Kishimoto Y Murakami M Shiraishi K Hayashi T Sekiya Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung Cancer Res 52 1992 4799 4804
7. AF Gazdar Molecular markers for the diagnosis and prognosis of lung cancer Cancer 69 1992 1592 1599
8. CC Harris Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies J Natl Cancer Inst 88 1996 1442 1455
9. SW Lowe HE Ruley T Jacks DE Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
10. SW Lowe EM Schmitt SW Smith BA Osborne T Jacks p53 is required for radiation-induced apoptosis in mouse thymocytes Nature 362 1993 847 852
11. V Rusch D Klimstra E Venkatraman J Oliver N Martini R Gralla Aberrant p53 expression predicts clinical resistance to cisplatinum-based chemotherapy in locally advanced non-small cell lung cancer Cancer Res 55 1995 5038 5042
12. EL Kaplan P Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. R Peto J Peto Asymptotically efficient rank invariant procedures J R Stat Soc 135 1972 185 207
14. TA Lehmann WP Bennett RA Metcalf JA Welsh J Ecker RV Modali p53 mutations, ras mutation, and p53–heat shock 70 protein complexes in human lung carcinoma cell lines Cancer Res 51 1991 4090 4096
15. JA Roth F Fossella R Komaki MB Ryan JB Putnam Jr LS Lee A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer J Natl Cancer Inst 86 1994 673 680
16. VW Rusch KS Albain JJ Crowley TW Rice V Lonchyna R McKenna Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemotherapy: a Southwest Oncology Group trial J Thorac Cardiovasc Surg 105 1993 97 106
17. RO Dillman SL Seagren KJ Propert J Guerra WL Eaton MC Perry A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N Engl J Med 323 1990 940 945
18. MS Greenblatt WP Bennett M Hollstein CC Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855 4878
19. MB Kastan CE Canman CJ Leonard p53, cell cycle control and apoptosis: implications for cancer Cancer Metastasis Rev 14 1995 3 15
20. CJ Fisher CE Gillett B Vojtesek DM Barnes RR Millis Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation Br J Cancer 69 1994 26 31
21. D Wynford-Thomas p53 in tumor pathology: can we trust immunohistochemistry? J Pathol 166 1992 329 330
22. S Sjögren M Inganäs T Norberg A Lindgren H Nordgren L Holmberg J Bergh The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry J Natl Cancer Inst 88 1996 173 182
23. R Salgia AT Skarin Molecular abnormalities in lung cancer J Clin Oncol 16 1998 1207 1217